GRI Bio, Inc. (GRI)

Market Cap	3.34M -24.9%
Revenue (ttm)	n/a
Net Income	-9.66M
EPS	-11.55
Shares Out	2.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,596
Open	1.590
Previous Close	1.570
Day's Range	1.450 - 1.590
52-Week Range	1.360 - 64.120
Beta	-0.61
Analysts	Strong Buy
Price Target	18.50 (+1,109.15%)
Est. Earnings	Nov 13, 2026

About GRI

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 4
• Stock Exchange: Nasdaq
• Ticker Symbol: GRI
• Website: https://www.gribio.com

Analyst Summary

According to 2 analysts, the average rating for GRI stock is "Strong Buy." The 12-month stock price target is $18.5, which is an increase of 1,109.15% from the latest price.

Price Target

$18.5

(1,109.15% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 31, 2026

Data Sources Report a data error